Trevi Therapeutics, Inc. Operating Lease Right-of-Use Assets
Trevi Therapeutics, Inc. (TRVI) had Operating Lease Right-of-Use Assets of $542.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Operating Lease, Right-of-Use Asset $542.00K.
- 2026-03-31: Operating Lease, Right-of-Use Asset $610.00K.
- 2025-12-31: Operating Lease, Right-of-Use Asset $677.00K.
- 2025-09-30: Operating Lease, Right-of-Use Asset $741.00K.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $542.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $610.00K 10-Q · filed 2026-05-05 |
| 2025-12-31 | $677.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $741.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $804.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $865.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $915.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $973.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.03M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.08M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.14M 10-K · filed 2025-03-18 |
| 2023-09-30 | $1.19M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.24M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $1.29M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $24.00K 10-K · filed 2024-03-20 |
| 2022-09-30 | $53.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $82.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $107.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $131.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $156.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $181.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $204.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $227.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $250.00K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $271.00K 10-Q · filed 2020-08-13 |
| 2020-03-31 | $292.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $312.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | $331.00K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $350.00K 10-Q · filed 2019-08-12 |
| 2019-03-31 | $368.00K 10-Q · filed 2019-06-14 |
| 2019-01-01 | $379.00K 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |